Cases & Deals

Takeover of Biotest AG by Chinese strategic investor Creat Group

Clients OGEL GmbH

Jones Day advised OGEL GmbH as holder of 50.61 percent of the Ordinary Shares in Biotest AG, Germany, in connection with the acquisition of Biotest by way of a public takeover offer made by a company controlled by CREAT Group, China. The enterprise value of Biotest is €1.203 billion. Biotest is a global company that supplies plasma protein products and biotherapeutic drugs.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.